| 杨二姣 潘琪 江虹 韩大芬 郑建华.两种高危型HPV检测技术诊断宫颈病变的临床价值比较[J].现代生物医学进展英文版,2015,15(4):653-655. |
| 两种高危型HPV检测技术诊断宫颈病变的临床价值比较 |
| Comparison of the Clinical Significances of two Kinds of High-risk TypeHPV Detection Technology in the Diagnosis of Cervical Lesions |
| |
| DOI： |
| 中文关键词: 酶切信号放大法 基因芯片技术 宫颈病变 宫颈上皮内瘤变2 级 临床价值 |
| 英文关键词: Enzyme cut signal amplification method(Cervista) Gene chip technology (HybriMa) Cervical lesions Cervical intraepithelial
neoplasia of grade 2 Clinical significance |
| 基金项目: |
|
| Hits: 1054 |
| Download times: 0 |
| 中文摘要: |
| 目的：比较酶切信号放大法(Cervista)与导流杂交基因芯片技术(HybriMa)检测高危型人乳头状瘤病毒(HR-HPV)诊断宫颈上
皮内瘤变2 级或2 级以上(CIN2+)的临床价值。方法：随机选择288 例2012年3 月至2013 年1 月在哈尔滨医科大学附属第一医
院妇科门诊进行新柏氏液基细胞学检查的年龄在20～65岁的宫颈细胞学检测未明确意义的不典型鳞状细胞(ASCUS)的患者，采
用Cervista 技术与HybriMa 技术进行高危型HPV 检测，并对入组的患者行阴道镜下宫颈活组织检查。以病理学诊断结果为金标
准，比较Cervista 技术与HybriMa 技术诊断宫颈上皮内瘤变2 级或2 级以上(CIN2+)的敏感度、特异度及ROC 曲线。结果：在入组
的288 例患者中，Cervista 技术和HybriMa 技术检出高危型HPV的阳性率分别为49.31%和51.39%(P>0.05)，其诊断CIN2+ 的敏
感度分别为95.65%和91.30%(P>0.05)，特异度分别为59.50%和56.20%(P>0.05)，阳性预计值分别为30.99%和28.38%(P>0.05)，阴
性预计值分别为98.63%和97.14%(P>0.05)。两组ROC 曲线下面积分别为0.776 和0.738(P>0.05)。结论：Cervista 技术与HybriMa
技术诊断CIN2+的临床价值相当。 |
| 英文摘要: |
| Objective:To compare the clinical significances of enzyme cut signal amplification method (Cervista) and diversion
hybrid gene chip technology (HybriMa) in the diagnosis of Cervical intraepithelial neoplasia of grade 2 or above(CIN2+).Methods:288
patients (aged 20～65) underwent cervical cytology for the detection of ASCUS (atypical squamous cells of uncertain meaning) and admitted
from March 2012 to January 2013 in the first affiliated hospital of Harbin medical university outpatient were selected, the finished
specimens of cervical cytology were used for the detection of residual with Cervista technology, diversion and hybridization, as well as
cervical biopsy under colposcope. A gold standard diagnosis based the pathological diagnosis results, the sensitivity, specificity and ROC
curves of Cervista and HybriMa technology in the diagnosis of CIN2+ were compared.Results:In the 288 patients, the positive rate of
Cervista technology and diversion type hybrid gene chip technology in the detection of high-risk HPV were 49.31% and 51.39% respectively
(P>0.05), the sensitivity of Cervista and HybriMa technology in the diagnosis of CIN2+ were 95.65 and 91.30%, respectively(P>0.
05), the specificity were 59.50%and 56.20%, respectively (P>0.05), the positive predictive value were 30.99%and 28.38%, respectively
(P>0.05), negative predictive value were 98.63%and 97.14%, respectively (P>0.05), and the area under ROC curve were 0.776 and 0.738,
respectively.Conclusion:The clinical significance of Cervista technology in the diagnosis of CIN2+ was equal to the HybriMa technology. |
|
View Full Text
View/Add Comment Download reader |
| Close |
